Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

NCT07287098 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07287098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Recruiting
Start date
May 13, 2026
Completion date
December 31, 2029
Enrollment
600 (estimated)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms